New MRI Procedure Can Accurately Classify or Rule Out Suspected Prostate Carcinoma
By MedImaging International staff writers Posted on 02 Mar 2015 |
A novel noninvasive Magnetic Resonance Imaging (MRI) method has been developed to detect or rule out prostate carcinomas.
The method, known as multi-parametric prostate MRI, enables physicians to probe prostate tissue cellular density, and anatomical features, and is the most reliable procedure currently available for accurate diagnosis of early-stage prostate carcinoma.
Prostate cancer is the second most common cause of death from cancer among men in the US, and the European Union, and an early accurate diagnosis helps minimizes the risk of adverse side effects, including incontinence, erectile dysfunction, and impotence.
Presently, patients that have a rising Prostate-Specific Antigen (PSA) value often undergo a Transrectal Ultrasound-guided (TRUS) biopsy. This method results in a 50% probability of detecting a carcinoma.
The new solution, developed by Siemens Healthcare (Erlangen, Germany), is the SEEit5, that includes Body 603 and Tim 4G coils and the Siemens RESOLVE application. The examination takes less than ten minutes, provides a highly accurate classification of the disease, and can rule out prostate cancer with a certainty of more than 89% percent. The SEEit5 solution uses the Siemens syngo MR E11 software architecture.
The radiologist reads and reports the results of the MRI scan using Siemens resyngo.via software, which supports the standard PI-RADS prostate cancer classification. The software displays the location of cancer-suspicious foci in a schematic drawing of the prostate.
Related Links:
Siemens Healthcare
The method, known as multi-parametric prostate MRI, enables physicians to probe prostate tissue cellular density, and anatomical features, and is the most reliable procedure currently available for accurate diagnosis of early-stage prostate carcinoma.
Prostate cancer is the second most common cause of death from cancer among men in the US, and the European Union, and an early accurate diagnosis helps minimizes the risk of adverse side effects, including incontinence, erectile dysfunction, and impotence.
Presently, patients that have a rising Prostate-Specific Antigen (PSA) value often undergo a Transrectal Ultrasound-guided (TRUS) biopsy. This method results in a 50% probability of detecting a carcinoma.
The new solution, developed by Siemens Healthcare (Erlangen, Germany), is the SEEit5, that includes Body 603 and Tim 4G coils and the Siemens RESOLVE application. The examination takes less than ten minutes, provides a highly accurate classification of the disease, and can rule out prostate cancer with a certainty of more than 89% percent. The SEEit5 solution uses the Siemens syngo MR E11 software architecture.
The radiologist reads and reports the results of the MRI scan using Siemens resyngo.via software, which supports the standard PI-RADS prostate cancer classification. The software displays the location of cancer-suspicious foci in a schematic drawing of the prostate.
Related Links:
Siemens Healthcare
Latest MRI News
- Low-Cost Whole-Body MRI Device Combined with AI Generates High-Quality Results
- World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
- World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
- Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
- Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
- PET/MRI Improves Diagnostic Accuracy for Prostate Cancer Patients
- Next Generation MR-Guided Focused Ultrasound Ushers In Future of Incisionless Neurosurgery
- Two-Part MRI Scan Detects Prostate Cancer More Quickly without Compromising Diagnostic Quality
- World’s Most Powerful MRI Machine Images Living Brain with Unrivaled Clarity
- New Whole-Body Imaging Technology Makes It Possible to View Inflammation on MRI Scan
- Combining Prostate MRI with Blood Test Can Avoid Unnecessary Prostate Biopsies
- New Treatment Combines MRI and Ultrasound to Control Prostate Cancer without Serious Side Effects
- MRI Improves Diagnosis and Treatment of Prostate Cancer
- Combined PET-MRI Scan Improves Treatment for Early Breast Cancer Patients
- 4D MRI Could Improve Clinical Assessment of Heart Blood Flow Abnormalities
- MRI-Guided Focused Ultrasound Therapy Shows Promise in Treating Prostate Cancer